#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News View on the Treatment of Rheumatoid Arthritis with Baricitinib Using the NNT Indicator

Clinical parameters assessed by patients themselves are an important tool in evaluating the effectiveness of new drugs and are particularly significant in the evaluation of treatments for chronic painful conditions, such as rheumatoid arthritis (RA). An analysis of clinical trial results presented at the European Rheumatology e-Congress in June 2020 focused on the effectiveness of the Janus kinase inhibitor baricitinib on parameters assessed directly by patients. Effectiveness was analyzed using the NNT indicator.
Source: Biological Treatment 30. 11. 2020

News Polatuzumab Vedotin in Combination Treatment of Patients with R/R DLBCL

Polatuzumab Vedotin is a conjugate of a cytostatic agent and an antibody against CD79b, a component of the B-lymphocyte receptor typically expressed by diffuse large B-cell lymphoma (DLBCL) cells. In combination with bendamustine and rituximab (pola-BR), this drug is administered in the 3rd and subsequent lines of treatment for relapsed or refractory (R/R) DLBCL. If allogeneic hematopoietic stem cell transplantation (HSCT) is not feasible, patients with R/R DLBCL generally have a very poor prognosis, with limited further treatment options. However, at the 61st American Society of Hematology (ASH) congress held in December 2019 in Orlando, promising results were presented from extended follow-up of patients treated in clinical studies with the pola-BR combination.
Source: Non-Hodgkin Lymphomas and CLL 3. 2. 2020

News Impact of Lifestyle on the Benefit of Pharmacotherapy for Hypertension and Dyslipidemia

Antihypertensive and hypolipidemic therapy reduces the risk of cardiovascular (CV) diseases. Observational studies have shown that factors of a healthy lifestyle also have this influence. But is the benefit of pharmacotherapy for hypertension and dyslipidemia influenced by adherence to a healthy lifestyle? This question was attempted to be answered by an analysis of data from the clinical study HOPE-3.
Source: Sartans in the Treatment of Hypertension 18. 4. 2020

News Rapid Diagnosis of Depression in Primary Care Settings

Depression is one of the most commonly occurring psychiatric disorders encountered in general practitioners' offices. The general public also very often uses the term “depression” to mean “bad mood.” Thus, a rapid diagnostic tool to identify “real depression” certainly deserves our attention.
Source: Depression and Anxiety 17. 3. 2020

News Trifluridine/tipiracil in Real Clinical Practice – Current Data from Spain

Trifluridine/tipiracil is indicated for the treatment of patients with refractory metastatic colorectal cancer (mCRC), where clinical studies have shown it extends overall survival (OS) and progression-free survival (PFS). At this year's virtual World Congress on Gastrointestinal Cancer of the European Society for Clinical Oncology (ESMO), held from June 30, a Spanish study on the efficacy of trifluridine/tipiracil in real-world clinical practice was presented.
Source: Treatment of Gastrointestinal Carcinomas 9. 9. 2021

News Bimekizumab in the Treatment of Psoriatic Arthritis

Arthritis can appear in up to a third of patients with psoriasis, mostly after the onset of skin symptoms. Early recognition of this transition by dermatologists and general practitioners is crucial, as early intervention can prevent irreversible joint damage. In the context of effective biological therapy, there is even talk of the potential prevention of arthritis development in individuals with psoriasis.
Source: Rheumatic Diseases 20. 6. 2024

News Doc. Petr Dulíček: Physical activity in hemophiliacs? Today it is a reality - just don't be afraid!

Thanks to modern treatment, the lives of hemophiliacs are becoming more active. Patients today can engage in most sports activities. On the contrary, avoiding physical activity carries the risk of developing other diseases. A doctor should support their patients so they are not afraid of physical activities and highlight their benefits, says the head of the Center for Hemostasis Disorders at the IV. Internal Hematology Clinic of LF UK and FN Hradec Králové, Doc. MUDr. Petr Dulíček, Ph.D., in an interview on hemophilia and sports.
Source: Hemophilia with Movement 30. 5. 2022

News Induction vs. Escalation Treatment: Which Strategy to Choose in the Therapy of Multiple Sclerosis?

Opinions on the optimal therapy for multiple sclerosis (MS) are constantly evolving, and experts are debating the most appropriate first-line treatment strategy. A British cohort study focused on the long-term outcomes of induction and escalation therapies, two key approaches in the treatment of MS.
Source: Multiple Sclerosis 25. 6. 2020

News Measurement of Serum Trough Levels of IgG as an Adequate and Beneficial Indicator for Assessing the Pharmacokinetics of Subcutaneously Administered Products

For many patients with primary immunodeficiency, lifelong immunoglobulin substitution is essential to reduce the frequency of severe infections. Subcutaneous home administration is better accepted by patients. However, dosing needs to be customized to the patient. The study presented below may help make therapy individualization easier for doctors and more tolerable for patients.
Source: Primary and Secondary Immunodeficiencies 11. 4. 2023

News Enoxaparin in Weight-Based Dosing for Thromboprophylaxis in Hospitalized Cancer Patients

Cancer patients are at higher risk of developing thromboembolic disease during hospitalization. Currently, there is not enough evidence supporting the efficacy and safety of the standard fixed dose of low molecular weight heparin in individuals at high risk of thromboembolic disease. Therefore, a Phase II clinical study evaluated the efficacy and safety of weight-adjusted dosing in these patients.
Source: Thromboprophylaxis 6. 11. 2020

News Maintenance Therapy After Oxaliplatin Discontinuation Based on Panitumumab

Panitumumab is an approved therapy for metastatic colorectal cancer without RAS oncogene mutation (wtRAS mCRC) and has been evaluated for 1st-line treatment through randomized phase II (PEAK) and III (PRIME) studies. A retrospective analysis of these studies assessed the efficacy and safety of panitumumab as the basis for therapy in these patients after discontinuation/termination of oxaliplatin.
Source: Colorectal Cancer 20. 2. 2020

News Should We Test for Alpha-1-Antitrypsin in All COPD Patients?

Approximately 1–2% of patients with chronic obstructive pulmonary disease (COPD) have an alpha-1-antitrypsin (AAT) deficiency. This is an underdiagnosed genetic disorder that leads to rapid progression of COPD, although it is initially amenable to therapeutic intervention. Therefore, it is necessary to improve early detection of affected individuals. General practitioners can play a crucial role in this process.
Source: Deficiency of Alpha-1-Antitrypsin 10. 2. 2020

News New Era in Migraine Therapy

Migraine is the most common type of primary headache. It affects about 10% of the world population. Recurring migraine attacks significantly reduce quality of life. Therefore, research in pharmacotherapy in recent years has logically focused on preventing attacks. The result is the latest possibility of biological treatment for migraines using monoclonal antibodies against CGRP receptors.
Source: Migraine 4. 5. 2020

News MS, NMOSD and COVID-19: What Did a Year of Pandemic in Czechia Mean for Our Patients and Which Risk Factors Were Confirmed?

What is the incidence and course of COVID-19 in patients with multiple sclerosis (MS) and diseases from the broader spectrum of neuromyelitis optica (NMOSD) in Czechia? And which risk factors pertain to this specific population? Data from the ReMuS registry, summarized in an article by Czech authors recently published in the journal Multiple Sclerosis and Related Disorders, revealed this and more. We offer a unique insight into the issue of COVID-19 in these patients in our conditions.
Source: Multiple Sclerosis 28. 7. 2021

News Non-Steroidal Anti-Inflammatory Drugs in the Treatment of Ankylosing Spondylitis: Network Meta-Analysis

A literature review and network meta-analysis of randomized controlled trials published in the journal Experimental and Therapeutic Medicine demonstrates the high efficacy and good tolerability of 6 non-steroidal anti-inflammatory drugs (NSAIDs) including etoricoxib, celecoxib, meloxicam, diclofenac, naproxen, and ß-D-mannuronic acid in the treatment of ankylosing spondylitis (AS).
Source: Updates in Pain Treatment 30. 3. 2023

News Prediabetes through the lens of current data and findings − and why hurry with intervention

Type 2 diabetes mellitus (DM2) is one of the most common causes of premature morbidity and mortality worldwide. The most serious impact on the health of the organism is mainly due to the macrovascular complications of this disease. However, their occurrence was often recorded before the diagnosis of DM2 was confirmed. Prediabetes itself thus represents a condition associated with the risk of developing cardiovascular (CV) complications with all their prognostic implications for patients.
Source: Diabetes 27. 7. 2022

News Micronutrients in Parenteral Nutrition in Adult Patients – Current Issues and Consensus

Micronutrients are a key nutritional component, and this is also true for patients whose condition requires the administration of parenteral nutrition. An article published last year in the Journal of Parenteral and Enteral Nutrition summarizes the expert literature on this topic as well as current guidelines and addresses 14 clinically most relevant questions related to the importance, administration, and monitoring of micronutrients.
Source: Parenteral Nutrition 23. 11. 2020

News Extended Thromboprophylaxis with Enoxaparin After Bariatric Surgery

A recent retrospective study involving 312 patients after bariatric surgery indicated that extended thromboprophylaxis might be an appropriate approach for preventing postoperative venous thromboembolism in these patients. In this study, the authors administered enoxaparin at a dose of 40 mg subcutaneously twice daily for 10-14 days in the majority of operated patients without an increased risk of bleeding.
Source: Thromboprophylaxis 29. 4. 2021

News What is the Impact of Bisoprolol on Plasma Concentrations of Dabigatran

Many patients on anticoagulant therapy with dabigatran also use the beta-blocker bisoprolol. The Slovak prospective observational study was based on the assumption that bisoprolol, as a significant inhibitor of P-glycoprotein, may interact with dabigatran and focused on examining the effect of this beta-blocker on plasma concentrations of dabigatran.
Source: Cardiovascular Continuum 16. 9. 2022

News Can alpha-1-antitrypsin deficiency affect severity and higher mortality in COVID-19 patients?

Alpha-1-antitrypsin (AAT) deficiency is commonly found in the European population. The most cases are recorded in countries with the highest COVID-19 mortality rates. Are there direct correlations?
Source: Deficiency of Alpha-1-Antitrypsin 12. 4. 2021

News Quality of Life of Patients on Adjuvant Treatment for HER2-Positive Breast Cancer

The KATHERINE clinical trial demonstrated that adjuvant therapy with trastuzumab emtansine compared to trastuzumab significantly improves invasive disease-free survival in patients with HER2-positive early breast cancer and residual invasive disease after prior treatment. A post hoc analysis of this study was published in the journal Cancer, focusing on patient-reported outcomes related to quality of life during and after treatment.
Source: Breast Carcinoma 28. 5. 2020

News What Did the Patent for the Synthesis of Highly Purified Trazodone Bring?

Trazodone is a modern antidepressant that is used in the treatment of various types of depression, including those accompanied by anxiety, sleep disorders, or sexual dysfunction. Angelini's invention, with patent protection valid until 2028, presents several methods for the preparation of purified trazodone, or trazodone hydrochloride, which guarantees high purity of this substance and a low content of unwanted residues.
Source: Depression and Anxiety 5. 10. 2020

News Biosimilar Bevacizumab in Patients with Non-Small Cell Lung Cancer

Biosimilar drugs are essentially analogous to generics for biological medicines. The patent protection for the original bevacizumab product will expire in the European Union in 2022. Consequently, several companies have already embarked on developing a biosimilar molecule.
Source: Oncological Treatment 15. 9. 2021

News Prophylaxis with Enoxaparin After Total Knee or Hip Replacement

Venous thromboembolic disease is a significant cause of complications in surgical patients during and after hospitalization. The authors of a recently published Portuguese observational study evaluated the incidence of complications with prophylaxis using low-molecular-weight heparin (LMWH) enoxaparin in a population after hip or knee joint replacement.
Source: Thromboprophylaxis 28. 11. 2023

News Finger on the Pulse of the Times with Automated Peritoneal Dialysis and Remote Patient Monitoring

The method of peritoneal dialysis brings many advantages to patients with chronic kidney disease and significantly eases their lives. Peritoneal dialysis saves time for both the patients themselves and the attending healthcare personnel. Modern medicine now offers an innovative tool that can remotely monitor the patient's condition, with the possibility of adjusting the treatment regimen.
Source: Chronic Kidney Disease 29. 9. 2020

1 26 27 28 29 30 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#